NO20091832L - Indoler som virker via reseptorantagonister - Google Patents

Indoler som virker via reseptorantagonister

Info

Publication number
NO20091832L
NO20091832L NO20091832A NO20091832A NO20091832L NO 20091832 L NO20091832 L NO 20091832L NO 20091832 A NO20091832 A NO 20091832A NO 20091832 A NO20091832 A NO 20091832A NO 20091832 L NO20091832 L NO 20091832L
Authority
NO
Norway
Prior art keywords
receptor antagonists
indoles
present
act via
via receptor
Prior art date
Application number
NO20091832A
Other languages
English (en)
Inventor
Patrick Schnider
Hasane Ratni
Caterina Bissantz
Christophe Grundschober
Mark Rogers-Evans
Rafaello Masciadri
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38983746&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20091832(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20091832L publication Critical patent/NO20091832L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

(I) Foreliggende oppfinnelse angår nye indol-2-yl-karbonyl-piperidin-benzoimidazolon- og indol-2-yl-karbonyl-piperidin-benzoksazolon-derivater som V1a reseptorantagonister, fremstilling av dem, farmasøytiske preparater inneholdende dem og anvendelse av dem som medikamenter. De aktive forbindelser ifølge foreliggende oppfinnelse er anvendelige for forebygging og/eller behandling av angst og depressive lidelser og andre sykdommer. Foreliggende oppfinnelse omfatter forbindelser med den generelle formel (I) hvor R1 til R11, X og Y er som definert i beskrivelsen.
NO20091832A 2006-12-08 2009-05-11 Indoler som virker via reseptorantagonister NO20091832L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06125663 2006-12-08
PCT/EP2007/062984 WO2008068184A1 (en) 2006-12-08 2007-11-29 Indoles which act as via receptor antagonists

Publications (1)

Publication Number Publication Date
NO20091832L true NO20091832L (no) 2009-07-07

Family

ID=38983746

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091832A NO20091832L (no) 2006-12-08 2009-05-11 Indoler som virker via reseptorantagonister

Country Status (21)

Country Link
US (4) US20080139618A1 (no)
EP (1) EP2089381B1 (no)
JP (1) JP2010511660A (no)
KR (1) KR101050558B1 (no)
CN (1) CN101541786A (no)
AR (1) AR064137A1 (no)
AT (1) ATE472544T1 (no)
AU (1) AU2007328994B2 (no)
BR (1) BRPI0720441A2 (no)
CA (1) CA2671324A1 (no)
CL (1) CL2007003503A1 (no)
DE (1) DE602007007512D1 (no)
ES (1) ES2345132T3 (no)
IL (1) IL198683A0 (no)
MX (1) MX2009005541A (no)
NO (1) NO20091832L (no)
PE (1) PE20081380A1 (no)
RU (1) RU2009120443A (no)
TW (1) TW200829570A (no)
WO (1) WO2008068184A1 (no)
ZA (1) ZA200903499B (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101050558B1 (ko) * 2006-12-08 2011-07-19 에프. 호프만-라 로슈 아게 Ｖ1ａ 수용체 길항제로서 작용하는 인돌
RU2009120136A (ru) * 2006-12-08 2011-01-20 Ф. Хоффманн-Ля Рош Аг (Ch) Индолы
PE20081401A1 (es) * 2006-12-28 2008-10-24 Hoffmann La Roche Derivados de indol como antagonistas de receptores vasopresina
EP2199967A1 (en) * 2008-12-08 2010-06-23 Electronics and Telecommunications Research Institute Apparatus for providing digital contents using dmb channel and method thereof
US20150376198A1 (en) * 2013-02-18 2015-12-31 The Scripps Research Institute Modulators of vasopressin receptors with therapeutic potential
GB201521059D0 (en) * 2015-11-30 2016-01-13 Isis Innovation Inhibitors of metallo-beta-lactamases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5924990B2 (ja) * 1979-11-21 1984-06-13 協和醗酵工業株式会社 新規なピペリジン誘導体
TW199153B (no) * 1990-08-07 1993-02-01 Dtsuka Seiyaku Kk
CA2166975C (en) * 1993-07-16 2005-04-05 Mark G. Bock Benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin receptor antagonists
CO5150201A1 (es) 1998-09-07 2002-04-29 Hoffmann La Roche Derivados de piperidina
JP2003532729A (ja) 2000-05-12 2003-11-05 ソルベイ・フアーマシユーチカルズ・ベー・ブイ ピペラジンおよびピペリジン化合物
JP2006505570A (ja) 2002-10-17 2006-02-16 アムジエン・インコーポレーテツド ベンズイミダゾール誘導体およびそれのバニロイド受容体リガンドとしての使用
PL1904477T3 (pl) 2005-07-14 2009-07-31 Hoffmann La Roche Pochodne indolo-3-karbonylo-spiro-piperydyny jako antagoniści receptora V1a
KR100984893B1 (ko) * 2005-07-21 2010-10-01 에프. 호프만-라 로슈 아게 Ｖ1ａ 수용체 길항제로서의인돌-3-일-카보닐-피페리딘-벤조이미다졸 유도체
ATE488519T1 (de) 2005-09-28 2010-12-15 Hoffmann La Roche Indol-3-ylcarbonylazaspiroderivate als vasopressinrezeptorantagonisten
KR101050558B1 (ko) * 2006-12-08 2011-07-19 에프. 호프만-라 로슈 아게 Ｖ1ａ 수용체 길항제로서 작용하는 인돌

Also Published As

Publication number Publication date
CL2007003503A1 (es) 2008-07-04
PE20081380A1 (es) 2008-09-18
IL198683A0 (en) 2010-02-17
RU2009120443A (ru) 2011-01-20
EP2089381A1 (en) 2009-08-19
US20080139617A1 (en) 2008-06-12
BRPI0720441A2 (pt) 2014-01-07
AU2007328994A1 (en) 2008-06-12
US20080139618A1 (en) 2008-06-12
US7799923B2 (en) 2010-09-21
AR064137A1 (es) 2009-03-18
JP2010511660A (ja) 2010-04-15
TW200829570A (en) 2008-07-16
US20080139548A1 (en) 2008-06-12
WO2008068184A1 (en) 2008-06-12
US20080269290A1 (en) 2008-10-30
EP2089381B1 (en) 2010-06-30
ATE472544T1 (de) 2010-07-15
CA2671324A1 (en) 2008-06-12
DE602007007512D1 (de) 2010-08-12
ES2345132T3 (es) 2010-09-15
AU2007328994B2 (en) 2012-03-08
MX2009005541A (es) 2009-06-05
US8071622B2 (en) 2011-12-06
CN101541786A (zh) 2009-09-23
ZA200903499B (en) 2010-03-31
KR20090078368A (ko) 2009-07-17
KR101050558B1 (ko) 2011-07-19

Similar Documents

Publication Publication Date Title
NO20092342L (no) Azaspiroderivativater
NO20091766L (no) Spiro-piperidinderivater
NO20073876L (no) Pyrazolopyrimidinderivater som mGluR2-antagonister
NO20074592L (no) Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister
NO20074258L (no) Pyridin-2-karboksamidderivater som MGLUR5 antagonister
NO20063599L (no) Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
NO20076195L (no) Nye 2-azetidinonderivater for behandling av hyperlipidemiske sykdommer
NO20070336L (no) Indolderivater som histamin-reseptorantagonister
NO20073665L (no) 2-fenoksy-N-(1,3,4-tiadizol-2-yl) Pyridin-3-aminderivater og beslektede forbindelser som P2Y1 reseptor inhibitorer for behandling av tromboemboliforstyrrelser
NO20063469L (no) Polyeheterosykliske forbindelser og deres anvendelse som metabotrofe glutamat reseptorantagonister
NO20076197L (no) Nye 2-azetidinonderivater anvendbare i behandling av hyperlipidemiske tilstander
NO20090266L (no) Piperazinylderivater anvendelige i behandlingen av GPR38 receptormedierte sykdommer
NO20064596L (no) Delta-krystallinsk form av ivabradin-hydroklorid, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den
WO2009010871A3 (en) Pyrazole derivatives as antagonists of adenosine a3 receptor
NO20084363L (no) 2-Substituerte 4-benzylftalazinonderivater som histamin H1- og H3-antagonister
NO20083905L (no) Nye pyron-indol derivater og fremgangsmate for deres fremstilling
NO20076060L (no) Piperidin-4-yl-amidderivater og deres anvendelse som SST-reseptor subtype 5-antagonister
EA200601194A1 (ru) Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором
EA200800421A1 (ru) Соединения
NO20091832L (no) Indoler som virker via reseptorantagonister
ATE542795T1 (de) Benzylpiperazinderivate als motilin- rezeptorantagonisten
NO20091831L (no) Indoler
NO20092149L (no) Spiro-piperidinderivater
NO20091830L (no) Spiro-piperidinderivater som VIa reseptorantagonister
EA200970553A1 (ru) Пиперидиниламинопиридазины и их применение в качестве быстро диссоциирующих антагонистов рецептора допамина 2

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application